

NCCN Multiple Myeloma Guidelines V.1.2013 – Update Teleconference– 05/22/12

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p>MYEL-D Internal request: Institutional Review comment requesting the use of lenalidomide for myeloma therapy in the maintenance setting as a category 1 recommendation.</p> <p>External request: Submission from Celgene Corp. Recommend the use of lenalidomide as a preferred regimen for myeloma therapy in the maintenance setting with a category 1 recommendation.</p>	<p>Based on the data from three phase III trials in the noted references and the panel consensus, lenalidomide was changed from a category 2A to a category 1 recommendation as an option for maintenance therapy.</p>	<p>Attal M, lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEJM 2012; 366(19):1782-91.</p> <p>McCarthy P, Owzar K, Hofmeister C, et al. lenalidomide after stem-cell transplantation for multiple myeloma. NEJM 2012; 366(19):1770-81.</p> <p>Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. NEJM 2012; 366(19):1759-69.</p>	13	0	0
<p>MYEL-D External request: Submission from Millennium Pharmaceuticals. Inclusion of a specific footnote for bortezomib.</p>	<p>Based on the noted reference and approved updates to the Velcade Prescribing Information, the panel consensus was to modify footnote 2 on MYEL-D by adding the following statement: “Consider using subcutaneous bortezomib for patients with pre-existing or high-risk peripheral neuropathy.”</p>	<p>Moreau P et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431-440.</p>	13	0	0
<p>MYEL-D External request: Submission from Millennium Pharmaceuticals. Inclusion of bortezomib + thalidomide as a category 1 recommendation for myeloma therapy in the maintenance</p>	<p>Based on the data in the noted reference(s), and the panel consensus, there was no change to this version of the guidelines.</p>	<p>Rosinol L et al. A Phase III PETHEMA/GEM Randomized trial of postransplant (ASCT) maintenance in multiple myeloma: superiority of bortezomib/thalidomide compared with thalidomide and alfa-2b interferon. Blood.2011;18(22):abstract#3962.</p>	0	13	0

NCCN Multiple Myeloma Guidelines V.1.2013 – Update Teleconference– 05/22/12

<p>setting.</p> <p>Inclusion of bortezomib + prednisone as a category 2A recommendation for myeloma therapy in the maintenance setting.</p>		<p>Mateos M-V et al. Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the GEM2005MAS65 spanish radnomized trial. Blood.2011;118(22):abstract#477.</p>			
<p>MYEL-D</p> <p>Internal request: Include bortezomib/ vorinostat as a regimen for myeloma therapy in the salvage therapy setting.</p> <p>External request: From Merck & Co. Inc. Review published literature on the use of vorinostat in multiple myeloma</p>	<p>Based on the data in the noted reference(s), the panel consensus was to include bortezomib/vorinostat as a salvage therapy option.</p>	<p>Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15:5250-5257.</p> <p>Siegel DS, Dimopoulos MA, Yoon S-S, et al. Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: Final study results of a global phase 2b trial. Blood 2011;118:480</p> <p>Dimopoulos MA, Jagannath S, Yoon S-S, et al. Vantage 088: Vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: Results of a global, randomized phase 3 trial [abstract]. Blood 2011;118:Abstract 811.</p>	<p>13</p>	<p>0</p>	<p>0</p>
<p>MYEL-D</p> <p>Internal request: Include lenalidomide/ bendamustine/dexamethasone as a regimen for myeloma therapy in the salvage therapy setting.</p>	<p>Based on the data in the noted reference(s), the panel consensus was to include bendamustine/lenalidomide/ /dexamethasone as a salvage therapy option.</p>	<p>Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly</p>	<p>13</p>	<p>0</p>	<p>0</p>

NCCN Multiple Myeloma Guidelines V.1.2013 – Update Teleconference– 05/22/12

		effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119:4608-4613.			
--	--	--	--	--	--

|